No CrossRef data available.
Article contents
Use of Bivalirudin for a Pediatric Patient with Two Mechanical Heart Valves: a case report
Published online by Cambridge University Press: 17 March 2025
Abstract
Despite advances in the development of systemic anticoagulants, there remain few agents approved for utilisation in patients with mechanical heart valves. Currently, recommendations for periprocedural and long-term anticoagulation in mechanical heart valves include unfractionated heparin or vitamin K antagonists, and there are some reports for off-label use of low-molecular-weight heparins. Emerging data on parenteral direct thrombin inhibitors, such as bivalirudin, have led to increased utilisation in both extracorporeal membrane oxygenation and ventricular assist devices. We present the case of a paediatric patient with rheumatic heart disease who had significant bleeding on unfractionated heparin who successfully received prolonged bivalirudin therapy in the setting of mechanical aortic and mitral heart valves.
- Type
- Brief Report
- Information
- Copyright
- © The Author(s), 2025. Published by Cambridge University Press
References
Otto, CM, Nishimura, RA, Bonow, RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: executive summary: a report of the American college of cardiology/American heart association joint committee on clinical practice guidelines. J Am Coll Cardiol 2021; 77 (
4
): 450–500.CrossRefGoogle Scholar
Douketis, JD, Berger, PB, Dunn, AS, et al. The perioperative management of antithrombotic therapy: American college of chest physicians evidence-based clinical practice guidelines. Chest 2008; 133 (
6
): 299S–339S.Google ScholarPubMed
Sanfilippo, F, Asmussen, S, Maybauer, DM, et al. Bivalirudin for alternative anticoagulation in extracorporeal membrane oxygenation: a systematic review. J Intensive Care Med 2017; 32 (
5
): 312–319.Google ScholarPubMed
Nagle, EL, Dager, WE, Duby, JJ, et al. Bivalirudin in pediatric patients maintained on extracorporeal life support. Pediatr Crit Care Med 2013; 14 (
4
): e182–e188.Google ScholarPubMed
Taylor, T, Campbell, CT, Kelly, B. A review of bivalirudin for pediatric and adult mechanical circulatory support. Am J Cardiovasc Drug 2021; 21: 395–409.Google ScholarPubMed
Mitchell, M, Sullinger, D, Dyer, D, et al. Evaluation of newly integrated bivalirudin titration protocol in patients with mechanical circulatory support. Ann Pharmacother 2024; 58 (
8
): 803–810.CrossRefGoogle ScholarPubMed
Rollins, AR, Smith, KE, Zemrak, WR. Implementation of a simplistic bivalirudin-warfarin transition protocol is associated with improved achievement of INR values within the therapeutic range. Ann Pharmacother 2016; 50 (
12
): 1001–1008.CrossRefGoogle ScholarPubMed
Fetea, A, Gulbis, BE, Hall, AC. Evaluation of bivalirudin’s effect on international Normalized ratio to determine an appropriate strategy for transitioning to warfarin. J Pharm Technol 2018; 34 (
3
): 117–122.CrossRefGoogle ScholarPubMed
Gosselin, RC, Dager, WE, King, JH, et al. Effect of direct thrombin inhibitors, bivalirudin, lepirudin, and argatroban, on prothrombin time and INR values. Am J Clin Pathol 2004; 121 (
4
): 593–599.Google ScholarPubMed